Pfizer’s Selzentry Wins FDA Approval For HIV
This article was originally published in The Pink Sheet Daily
Executive Summary
First-in-class CCR5 antagonist will be available by mid-September with a wholesale acquisition cost of $29/day based on twice-a-day dosing, Pfizer tells “The Pink Sheet” DAILY.
You may also be interested in...
Selzentry Advisory Committee To Weigh Virologic Resistance Vs. Adverse Events
Pfizer wants to expand the indication of its HIV drug to treatment-naive patients, but FDA wants the panel's advice on what the standards for such a claim should be.
Selzentry Advisory Committee To Weigh Virologic Resistance Vs. Adverse Events
Pfizer wants to expand the indication of its HIV drug to treatment-naive patients, but FDA wants the panel's advice on what the standards for such a claim should be.
Reanalyzed MERIT Data Suggests Selzentry Efficacy Matches HIV Standard Of Care
Enhanced Trofile assay reveals previous data included patients with HIV variants who should have been excluded, Pfizer and Monogram Biosciences report at ICAAC.